Can You Take Deferiprone with PNV 27-Ca/Fe/FA?

Food may reduce the absorption and blood levels of multivitamin, prenatal. In addition, some oral medications can also interfere with multivitamin, prenatal absorption into the bloodstream, which may make the medication less effective in treating your condition. Likewise, multivitamin, prenatal may interfere with the absorption of other orally administered medications. You should take multivitamin, prenatal on an empty stomach at least one hour before or two hours after a meal. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Talk to your doctor or pharmacist if you have questions about how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Fatal agranulocytosis and neutropenia can occur with the use of deferiprone. It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate. Manage agranulocytosis/neutropenia prior to initiating treatment. Therapy should be interrupted if neutropenia develops or if an infection develops. Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.

Fatal agranulocytosis and neutropenia can occur with the use of deferiprone. It is recommended to obtain an absolute neutrophil count before initiating treatment with deferiprone and monitor weekly thereafter or as clinically appropriate. Manage agranulocytosis/neutropenia prior to initiating treatment. Therapy should be interrupted if neutropenia develops or if an infection develops. Do not resume therapy in patients who have developed agranulocytosis and do not rechallenge patients who develop neutropenia unless potential benefits outweigh potential risks.

A clinical study to evaluate the effect of impaired hepatic function on the pharmacokinetics of deferiprone showed that mild and moderate hepatic impairment do not influence the pharmacokinetics of deferiprone and major metabolite, deferiprone 3-O-glucuronide. Based on the results, no dose adjustment is required in patients with mildly or moderately hepatic impairment. Caution is recommended when using this agent in patients with severe hepatic impairment as the pharmacokinetics of deferiprone and deferiprone have not been evaluated. It is recommended to monitor serum transaminase values monthly during therapy and to consider interruption if there is a persistent increase in serum transaminase levels. Close monitoring is recommended.